Hypoxia contributes to galectin-3 expression in renal carcinoma cells

Gu, Xin; Meng, Hongxue; Wang, Jia; Cao, Muyang; Liu, Siyu; Chen, Hui; Xu, Yangyang

doi:10.1016/j.ejphar.2020.173637

Cited by 13 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned earlier, several previous studies have highlighted reciprocal influences of metabolic regulations on the one hand and gal-1, -3 and -9 expression and activity on the other hand (Darrow and Shohet 2015, de Oliveira, Ribeiro et al 2015, Wang, Li et al 2020, Chang, Xu et al 2021, Gu, Meng et al 2021. Therefore, we investigated whether some plasmatic metabolites were preferentially associated with high concentrations of gal-1, -3 and -9 and/or with a specific tumor category.…”

Section: High Levels Of Plasma Kinurenine Linked To High Concentratio...mentioning

confidence: 85%

“…There are also data suggesting reciprocal interactions between galectin production and metabolic alterations occurring in the context of malignant diseases. For example, hypoxia has been shown to enhance gal-3 expression in malignant cells and/or tumor-associated macrophages (TAMs) in various types of malignancies (de Oliveira, Ribeiro et al 2015, Wang, Li et al 2020, Gu, Meng et al 2021. Reciprocally, gal-3 facilitates the uptake of glucose especially in endothelial cells at least in part by up-regulation of the membrane transporter Glut-4 (Darrow and Shohet 2015).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors

et al. 2022

View full text Add to dashboard Cite

Extra-cellular galectins 1, 3 and 9 (gal-1, −3 and −9) are known to act as soluble immunosuppressive agents in various malignancies. Previous publications have suggested that their expression is dependent on the metabolic status of producing cells and reciprocally that they can influence metabolic pathways in their target cells. Very little is known about the status of gal-1, −3 and −9 in patients bearing head and neck squamous cell carcinomas (HNSCC) and about their relationships with the systemic metabolic condition. This study was conducted in plasma samples from a prospective cohort of 83 HNSCC patients with advanced disease. These samples were used to explore the distribution of gal-1, −3 and −9 and simultaneously to profile a series of 87 metabolites assessed by mass spectrometry. We identified galectin and metabolic patterns within five disease categories defined according to the primary site and human papillomavirus (HPV) status (HPV-positive and -negative oropharyngeal carcinomas, carcinomas of the oral cavity, hypopharynx and larynx carcinomas). Remarkably, samples related to hypopharyngeal carcinomas displayed the highest average concentration of gal-9 ( p = .017 ) and a trend toward higher concentrations of kynurenine, a potential factor of tumor growth and immune suppression. In contrast, there was a tendency toward higher concentrations of fatty acids in samples related to oral cavity. These observations emphasize the diversity of HPV-negative HNSCCs. Depending on their primary site, they evolve into distinct types of immune and metabolic landscapes that seem to be congruent with specific oncogenic mechanisms.

show abstract

Section: High Levels Of Plasma Kinurenine Linked To High Concentratio...mentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In renal carcinoma cells, Gal-3 shows that hypoxia is crucial for its expression, and its level elevates gradually with disease stage [72]. Gal-3 is also connected to immuneassociated kidney damage like sepsis, cancer, or autoimmune diseases [71,73]. At the cellular level, Gal-3 is associated with renal fibrogenesis and chronic inflammation [74,75].…”

Section: Serum Markersmentioning

confidence: 99%

On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients—A Systematic Review

Nikitiuk,

Rydzewska-Rosołowska,

Kakareko

et al. 2024

IJMS

View full text Add to dashboard Cite

Overhydration (OH) is a prevalent medical problem that occurs in patients with kidney failure, but a specific marker has still not been found. Patients requiring kidney replacement therapy suffer from a water imbalance, which is correlated with mortality rates in this population. Currently, clinicians employ techniques such as bioimpedance spectroscopy (BIS) and ultrasound (USG) markers of overhydration or markers of heart and kidney function, namely NT-pro-BNP, GFR, or creatinine levels. New serum markers, including but not limited to Ca-125, galectin-3 (Gal-3), adrenomedullin (AMD), and urocortin-2 (UCN-2), are presently under research and have displayed promising results. Ca-125, which is a protein mainly used in ovarian cancer diagnoses, holds great potential to become an OH marker. It is currently being investigated by cardiologists as it corresponds to the volume status in heart failure (HF) and ventricular hypertrophy, which are also associated with OH. The need to ascertain a more precise marker of overhydration is urgent mainly because physical examinations are exceptionally inaccurate. The signs and symptoms of overhydration, such as edema or a gradual increase in body mass, are not always present, notably in patients with chronic kidney disease. Metabolic disruptions and cachexia can give a false picture of the hydration status. This review paper summarizes the existing knowledge on the assessment of a patient’s hydration status, focusing specifically on kidney diseases and the role of Ca-125.

show abstract

“…In pre-clinical models, it is overexpressed in diabetic nephropathy, toxic injury, cardiorenal syndrome or ischemia/reperfusion injury. In renal carcinoma cells, Gal-3 shows that hypoxia is crucial for its expression and its level elevates gradually with a disease stage [59]. Gal-3 is also connected to immune-associated kidney damage like sepsis, cancer or autoimmune diseases [58,60].…”

Section: D)mentioning

confidence: 99%

Is Modern Medicine in Need of an Overhydration Marker in Kidney Failure? The Accuracy of Available Fluid Overload Markers and the Potential of the New Ones

Nikitiuk,

Rydzewska-Rosołowska,

Kakareko

et al. 2023

Preprint

View full text Add to dashboard Cite

Overhydration (OH) is a common medical problem found in patients with kidney or heart failure, but still a specific marker has not been found. Clinicians today use bioimpedance spectroscopy (BIS), ultrasound (US) markers of fluid overload or markers of heart and kidney function like NT-pro-BNP, GFR or creatinine levels. New serum markers such as Ca-125, Galectin-3 (Gal-3), Adrenomedullin (AMD) and Urocortin-2 (UCN-2), are being researched with promising results. The need to discover a more precise marker of overhydration is dire mainly because physical examination is extremely imprecise. Signs and symptoms of fluid overload like edema or gradual increase of body mass are not always present, especially in patients with chronic kidney disease. This review paper summarizes actual knowledge of a patient's hydration status estimation focusing especially on kidney diseases.

show abstract

Hypoxia contributes to galectin-3 expression in renal carcinoma cells

Cited by 13 publications

References 37 publications

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors

On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients—A Systematic Review

Is Modern Medicine in Need of an Overhydration Marker in Kidney Failure? The Accuracy of Available Fluid Overload Markers and the Potential of the New Ones

Contact Info

Product

Resources

About